Teclistamab has received conditional approval in the EU for the treatment of adult patients with r/r MM who have received three or more prior therapies (including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody) and have demonstrated disease progression on the last therapy. Here, CD38 is linked to Miyoshi myopathy.